TR201713954A2 - Tenofovir, emtrisitabin ve efavirenzin farmasötik kombinasyonlari - Google Patents
Tenofovir, emtrisitabin ve efavirenzin farmasötik kombinasyonlari Download PDFInfo
- Publication number
- TR201713954A2 TR201713954A2 TR2017/13954A TR201713954A TR201713954A2 TR 201713954 A2 TR201713954 A2 TR 201713954A2 TR 2017/13954 A TR2017/13954 A TR 2017/13954A TR 201713954 A TR201713954 A TR 201713954A TR 201713954 A2 TR201713954 A2 TR 201713954A2
- Authority
- TR
- Turkey
- Prior art keywords
- tenofovir
- emtrisitabin
- eavirenzine
- pharmaceutical combinations
- pharmaceutically acceptable
- Prior art date
Links
- 229960004556 tenofovir Drugs 0.000 title abstract 2
- SGOIRFVFHAKUTI-ZCFIWIBFSA-N tenofovir (anhydrous) Chemical compound N1=CN=C2N(C[C@@H](C)OCP(O)(O)=O)C=NC2=C1N SGOIRFVFHAKUTI-ZCFIWIBFSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 3
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 abstract 1
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 abstract 1
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 abstract 1
- 229960003804 efavirenz Drugs 0.000 abstract 1
- 229960000366 emtricitabine Drugs 0.000 abstract 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Mevcut buluş, tenofovir veya onun farmasötik olarak kabul edilebilir bir tuzunu, emtrisitabin veya onun farmasötik olarak kabul edilebilir bir tuzunu ve efavirenz veya onun farmasötik olarak kabul edilebilir bir tuzunu içeren çentikli bir çift katmanlı tablet ile ilgilidir.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2017/13954A TR201713954A2 (tr) | 2017-09-20 | 2017-09-20 | Tenofovir, emtrisitabin ve efavirenzin farmasötik kombinasyonlari |
EP18840094.9A EP3684341A2 (en) | 2017-09-20 | 2018-09-19 | Pharmaceutical combinations of tenofovir, emtricitabine and efavirenz |
PCT/TR2018/050508 WO2019059868A2 (en) | 2017-09-20 | 2018-09-19 | PHARMACEUTICAL COMBINATIONS OF TENOFOVIR, EMTRICITABINE AND EFAVIRENZ |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2017/13954A TR201713954A2 (tr) | 2017-09-20 | 2017-09-20 | Tenofovir, emtrisitabin ve efavirenzin farmasötik kombinasyonlari |
Publications (1)
Publication Number | Publication Date |
---|---|
TR201713954A2 true TR201713954A2 (tr) | 2019-04-22 |
Family
ID=65237119
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2017/13954A TR201713954A2 (tr) | 2017-09-20 | 2017-09-20 | Tenofovir, emtrisitabin ve efavirenzin farmasötik kombinasyonlari |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3684341A2 (tr) |
TR (1) | TR201713954A2 (tr) |
WO (1) | WO2019059868A2 (tr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114948970A (zh) * | 2022-06-07 | 2022-08-30 | 安徽贝克生物制药有限公司 | 含依非韦伦的药物组合物及其制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE398455T1 (de) | 2003-01-14 | 2008-07-15 | Gilead Sciences Inc | Zusammensetzungen und verfahren zur antiviralen kombinationstherapie |
TWI375560B (en) * | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
TWI471145B (zh) * | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
WO2008096369A2 (en) * | 2007-02-05 | 2008-08-14 | Matrix Laboratories Limited | Pharmaceutical formulation for use in hiv therapy |
-
2017
- 2017-09-20 TR TR2017/13954A patent/TR201713954A2/tr unknown
-
2018
- 2018-09-19 EP EP18840094.9A patent/EP3684341A2/en active Pending
- 2018-09-19 WO PCT/TR2018/050508 patent/WO2019059868A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3684341A2 (en) | 2020-07-29 |
WO2019059868A2 (en) | 2019-03-28 |
WO2019059868A3 (en) | 2019-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017502431A1 (en) | Pharmaceutical formulations comprising tenofovir and emtrictabine | |
CY1123571T1 (el) | Βουπροπιονη για τη ρυθμιση των φαρμακευτικων επιπεδων δεξτρομεθορφανης στο πλασμα | |
CY1124007T1 (el) | Στοματικες δοσολογικες μορφες παρατεταμενης απελευθερωσης τοφασιτινιμπης | |
EA201792591A1 (ru) | Фармацевтические препараты | |
CY1121999T1 (el) | Φαρμακοτεχνικες μορφες συνδυασμου δαρουναβιρης | |
EA201390662A1 (ru) | Фармацевтическая композиция, содержащая дутастерид | |
CY1115556T1 (el) | Φαρμακευτικη συνθεση για χορηγηση απο το στομα η οποια περιλαμβανει ετεξιλικη δαβιγατρανη | |
CY1124041T1 (el) | Συνθεσεις που περιλαμβανουν κυκλοσπορινη | |
TR201916829A2 (tr) | Dapagli̇flozi̇n ve metformi̇n i̇çeren çi̇ft katmanli tablet formülasyonlari | |
CY1119446T1 (el) | Φαρμακοτεχνικες μορφες δαρουναβιρης | |
EA202090542A1 (ru) | Высококонцентрированные лекарственные формы придопидина | |
MX2016002560A (es) | Forma de dosificacion unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolitico que comprende darunavir y ritonavir. | |
EA202090913A1 (ru) | Композиция таблеток с модифицированным высвобождением, содержащая мирабегрон | |
TR201914043A1 (tr) | Dapagli̇flozi̇n ve metformi̇n i̇çeren efervesan tablet formülasyonlari | |
TR201713954A2 (tr) | Tenofovir, emtrisitabin ve efavirenzin farmasötik kombinasyonlari | |
TR201721700A2 (tr) | Saksagli̇pti̇ni̇n ağizda dağilan formülasyonlari | |
CY1120192T1 (el) | Ενωσεις για την ενισχυση της γνωστικης λειτουργιας | |
EA201991286A1 (ru) | Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин | |
TR201007926A1 (tr) | Prasugrel tablet formülasyonları. | |
EA201691422A1 (ru) | Перорально распадающиеся таблетированные составы мемантина | |
IN2013MU03370A (tr) | ||
EA201991007A1 (ru) | Твердые фармацевтические композиции на основе гидрохлорида луразидона для перорального применения | |
TR201721036A2 (tr) | Flurbi̇profeni̇n modi̇fi̇ye salimli formülasyonlari | |
TR201721824A2 (tr) | Li̇nagli̇pti̇n ve metformi̇n i̇çeren modi̇fi̇ye salim sağlayan kombi̇nasyon | |
JOP20170198A1 (ar) | صيغ صيدلية تشتمل على تينوفوفير و إيمترايسيتابين |